India to Thailand: Amiodarone Export Trade Route

To import finished pharmaceutical formulations containing Amiodarone into Thailand, compliance with the Thai Food and Drug Administration (FDA) regulations is mandatory. The process involves several key steps:

1. Drug Facility Licensing: Importers must obtain a license from the Thai FDA. Applications are submitted to the FDA for facilities in Bangkok or to the Provincial Public Health Office for facilities in other provinces. Licensed facilities must have a pharmacist present during operations. Licenses require annual renewal, with fees varying based on the facility type. (en.fda.moph.go.th)

2. Pharmaceutical Product Registration: Each finished pharmaceutical product, including Amiodarone formulations, must be registered with the Thai FDA before importation. The registration dossier should follow the ASEAN Common Technical Dossier (ACTD) or the International Council for Harmonisation Common Technical Document (ICH CTD) formats. The registration process includes submitting an application form (Form Yor.1), drug samples, and technical documents demonstrating the product's quality, efficacy, and safety. Consultation with the Medicines Regulation Division is recommended to ensure thorough preparation. Fees are applicable during the application process. (en.fda.moph.go.th)

3. GMP Clearance for Overseas Manufacturers: Foreign manufacturing facilities producing Amiodarone formulations must obtain Good Manufacturing Practice (GMP) Clearance from the Thai FDA. This involves demonstrating compliance with GMP standards recognized by the Thai FDA. The GMP Clearance is a prerequisite for product registration and importation. (en.fda.moph.go.th)

Indian exporters of Amiodarone formulations must adhere to stringent quality and GMP standards to access the Thai market:

1. GMP Certification: Manufacturing facilities must comply with internationally recognized GMP standards. The Thai FDA requires evidence of such compliance, which may include certifications from recognized bodies. (en.fda.moph.go.th)

2. GMP Clearance Application: Indian manufacturers must apply for GMP Clearance from the Thai FDA, providing comprehensive documentation of their manufacturing processes, quality control measures, and compliance with GMP standards. The Thai FDA evaluates these applications to ensure that the facilities meet the required standards. (en.fda.moph.go.th)

3. Inspections and Compliance: The Thai FDA may conduct inspections of foreign manufacturing facilities to verify GMP compliance. Maintaining up-to-date GMP certifications and being prepared for potential inspections are crucial for continued market access. (en.fda.moph.go.th)

In the past 18 months, several regulatory developments have impacted pharmaceutical imports into Thailand:

1. Updated Guidelines for Personal Importation: In November 2024, the Thai FDA issued traveler-friendly guidelines for importing personal health products, including medications, into Thailand. These guidelines aim to facilitate a smoother entry process for tourists and ensure compliance with health and safety standards.

2. Quality System Regulations for Medical Devices: In April 2024, the Thai FDA issued notifications regarding Good Manufacturing Practice (GMP) and Good Importing and Sales Practice (GISP) for medical devices. While these regulations primarily target medical devices, they reflect the Thai FDA's ongoing commitment to stringent quality standards across all health-related products.

Staying informed about these regulatory changes is essential for Indian exporters to ensure compliance and maintain uninterrupted access to the Thai pharmaceutical market.

TARIFF_NOTES: Pharmaceutical imports under HS code 30049099 are exempt from import duties in Thailand, facilitating the importation of essential medicines.

Amiodarone is a critical antiarrhythmic medication used to manage various types of cardiac arrhythmias. In Thailand, the demand for Amiodarone formulations is influenced by the prevalence of cardiovascular diseases, an aging population, and the country's commitment to universal health coverage. As of 2024, cardiovascular diseases remain a leading cause of morbidity and mortality in Thailand, necessitating a steady demand for effective treatments like Amiodarone.

While specific market size data for Amiodarone in Thailand is not readily available, the country's import data provides insight into its reliance on foreign suppliers. In 2024, Thailand imported finished pharmaceutical formulations containing Amiodarone valued at $0.9 million USD from India alone, accounting for 1.3% of India's total Amiodarone formulation exports. This indicates a significant dependence on imports to meet domestic demand. Domestic manufacturing of Amiodarone formulations exists but is limited, with imports playing a crucial role in supplementing local production to ensure adequate supply.

Thailand maintains a 0% MFN import duty rate for pharmaceutical products classified under HS code 30049099, which includes finished Amiodarone formulations. This policy underscores the country's commitment to making essential medicines accessible and affordable. Additionally, Thailand and India are both members of the ASEAN-India Free Trade Area (AIFTA), which further facilitates trade between the two nations by reducing or eliminating tariffs on various products, including pharmaceuticals. As a result, imports of Amiodarone formulations from India benefit from preferential tariff rates, enhancing the cost-effectiveness of these imports.

India is a major supplier of Amiodarone formulations to Thailand, with exports valued at $0.9 million USD in 2024. While specific data on other supplying countries is limited, it is known that Thailand also imports pharmaceutical products from countries such as China and various European Union (EU) member states. India's share of Thailand's total Amiodarone imports is significant, reflecting its competitive pricing and established pharmaceutical manufacturing capabilities. Indian pharmaceutical companies are known for producing high-quality generic medications at competitive prices, often undercutting prices from manufacturers in China and the EU. This pricing advantage, coupled with the benefits of the AIFTA, positions India as a key player in supplying Amiodarone formulations to the Thai market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the world's generic drug supply. This extensive manufacturing capability includes a significant production of finished dosage forms containing Amiodarone, such as tablets and injections. The country's cost-effective production is attributed to economies of scale, competitive labor costs, and a well-established supply chain for pharmaceutical ingredients. As of November 2024, India had 134 FDA-registered facilities dedicated to finished dosage forms, underscoring its commitment to quality and regulatory compliance.

When comparing Amiodarone formulations from India, China, and the European Union (EU), several factors emerge:

• Cost: India offers competitive pricing for finished dosage forms due to its efficient manufacturing processes and lower production costs. China, while also cost-effective, primarily focuses on active pharmaceutical ingredients (APIs) rather than finished formulations. The EU, known for high-quality standards, typically presents higher prices for branded generics.

• Quality Perception: Indian pharmaceutical manufacturers have a strong reputation for quality, with numerous facilities approved by international regulatory bodies, including the FDA and WHO. China's focus on APIs means fewer finished dosage facilities with such approvals. The EU maintains stringent quality standards, contributing to its higher pricing.

• Regulatory Acceptance in Thailand: Thailand's regulatory framework recognizes and accepts pharmaceuticals from India, facilitated by India's adherence to international quality standards. Chinese formulations may face more scrutiny due to quality concerns, while EU products are readily accepted but at a higher cost.

• Supply Reliability: India has a proven track record of reliable supply chains for finished pharmaceutical formulations, supported by robust manufacturing capacities and regulatory compliance. China's focus on APIs and the EU's higher costs can impact their supply reliability for finished dosage forms.

The India-Thailand supply chain for Amiodarone formulations is robust, supported by India's substantial manufacturing capacity and compliance with international regulatory standards. Indian manufacturers have demonstrated consistent supply reliability, with no significant disruptions reported in recent years. Facilities are equipped with advanced packaging and cold chain capabilities to ensure product integrity during transit. Leading manufacturers continue to expand their capacities to meet growing global demand, indicating a stable and scalable supply chain.

For Thai buyers sourcing Amiodarone formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure continuous availability.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Familiarize yourself with common payment terms in India-Thailand pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to facilitate smooth transactions.

• Supplier Qualification Process: Implement a rigorous supplier qualification process, including audits of manufacturing facilities, verification of regulatory approvals, and assessment of quality control systems.

• Regulatory Compliance: Ensure that selected suppliers comply with both Indian and Thai regulatory requirements, including necessary certifications and documentation for importation.

By adopting these strategies, Thai buyers can establish a reliable and cost-effective supply chain for Amiodarone formulations from India.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming it meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for regulatory and tariff purposes.

3. GMP Certificate: Evidence that the manufacturing facility complies with GMP standards, ensuring consistent product quality.

4. Stability Data: Demonstrates the product's shelf life and stability under various environmental conditions, crucial for storage and distribution planning.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and compliance with manufacturing protocols.

6. Drug Master File (DMF): Comprehensive document submitted to regulatory authorities, detailing the manufacturing process, controls, and specifications of the drug product.

7. Free Sale Certificate: Issued by CDSCO, indicating that the product is approved for sale in India and complies with local regulations.

8. Insurance Certificates: Proof of liability insurance coverage, providing assurance of financial responsibility in case of product-related issues.

Implementing this structured approach will help Thailand companies ensure that their Indian Amiodarone suppliers meet the necessary quality and regulatory standards, thereby safeguarding product integrity and patient health.